More than Money: Shield Therapeutics
It is very unusual to find a small British pharma company which has managed to get a drug approved in the US. Shield Therapeutics (LON: STX) will have defied the odds if it gets a positive response back from the FDA on 27 July. We spoke to the group's founder and chief executive about the challenges of getting a drug approved in the world's biggest healthcare market and the commercial opportunities for those that make it.
Sign up for more great content
Register to continue reading our content.
Already a member? Login
Previous article Next article